THE MEDICINE

5-MeO

A fast-acting, deeply transformative medicine with growing clinical evidence for PTSD, depression, and trauma recovery , central to our protocol for nearly a decade.

ON THIS PAGE

  1. What It Is

  2. Why People Are Paying Attention

  3. What a Session Is Like

  4. How It May Work

  5. Legal Status & Access

  6. Safety

  7. What the Evidence Says

  8. The Conservation Question

  9. Clinical History

  10. Sources

01

What It Is

5-MeO (5-methoxy-N,N-dimethyltryptamine) is a naturally occurring psychedelic compound found in a variety of plant species and, in high concentrations, in the secretion from the Sonoran Desert toad (Incilius alvarius, also called the Colorado River toad). It is also known by the names "Bufo," "Five," "toad venom," and, colloquially, the "God molecule." Journalist Michael Pollan has called it the "Mount Everest of psychedelics."

The compound was first synthesized in 1936 and has a history of use in South American indigenous traditions, where plants containing it were prepared as shamanic snuffs and inhaled for ritual and healing purposes. Use of toad-derived secretionsvenom became more widely documented in the 1980s in the southwestern United States and northern Mexico.

02

Why People Are Paying Attention

Researchers and clinicians are exploring 5-MeO for its potential to treat depression, post-traumatic stress disorder (PTSD), and other treatment-resistant mental health conditions. What distinguishes it from better-known psychedelics like psilocybin and MDMA is its exceptionally short duration - a typical session lasts 20 to 60 minutes - which has generated significant interest from drug developers and clinicians who see it as a more feasible option for clinical delivery.

Scientists, veterans, and people with treatment-resistant depression have reported meaningful improvements after a single session, and clinical trial data is now beginning to support those accounts.

03

What a Session Is Like

5-MeO is most commonly inhaled as a vaporized substance and produces effects within seconds. The peak experience typically arrives within 15 to 30 seconds, with peak effects lasting 5 to 15 minutes, and resolving within 30 to 60 minutes. Users frequently describe the experience as profound and disorienting - characterized by ego dissolution (a loss of the sense of self), feelings of unity or oneness, auditory and visual alterations, and what researchers call a "complete mystical experience." Nausea and overwhelming subjective effects are also commonly reported.

Unlike the 6 to 8-hour sessions associated with psilocybin-assisted therapy, 5-MeO interventions can be completed in under an hour, making them potentially more scalable within existing clinical infrastructure.

04

How It May Work

5-MeO acts primarily as an agonist at serotonin receptors in the brain, especially 5-HT1A and 5-HT2A receptors - though it has a notably different receptor profile from most classic psychedelics like LSD and psilocybin, which act primarily through 5-HT2A activation. Researchers hypothesize that the intense ego-dissolution 5-MeO produces, and the mystical experiences it occasions, may underlie its therapeutic effects - similar to mechanisms proposed for psilocybin. Effects on neuroplasticity (the brain's capacity to form new connections and reorganize) are also under investigation.

Note: Biological mechanisms are still being studied. Clinical trials are ongoing, and the full picture of how and why 5-MeO produces therapeutic effects remains an active area of research.

05

Legal Status & Access

5-MeO is a Schedule I controlled substance under U.S. federal law, making it illegal to manufacture, possess, or distribute without a DEA license. It was formally scheduled in January 2011. Researchers wishing to study synthetic 5-MeO must obtain special government permits.

People seeking access to 5-MeO experiences often travel to countries like Mexico, the Netherlands, or Portugal, where the compound exists in legal gray areas or has been decriminalized. Retreat programs are common in northern Mexico, particularly near the U.S. border. Some religious organizations in the U.S. have sought exemptions under the Religious Freedom Restoration Act, following precedents set for ayahuasca use by the Supreme Court in 2006.

Note: The legal status of toad-derived 5-MeO is not different from synthetic versions under U.S. federal law - the compound itself is controlled regardless of its source.

06

Safety

Existing clinical trial data - while limited in sample size - has shown a favorable short-term safety and tolerability profile for 5-MeO, with no serious adverse events reported in published trials. Common adverse effects include transient nausea, rapid heart rate and blood pressure changes, and intense psychological distress during the experience.

The most significant known safety risks arise from drug interactions, particularly with monoamine oxidase inhibitors (MAOIs) - a class of antidepressants. Combining 5-MeO with MAOIs can trigger serotonin syndrome, a potentially life-threatening condition that can present as muscle rigidity, high fever, and seizure. There have been documented deaths from this combination. Lithium is also contraindicated due to seizure risk. SSRIs are not considered acutely dangerous in combination but may reduce the compound's therapeutic effects.

People with a personal or family history of schizophrenia, schizoaffective disorder, or psychotic episodes are generally considered poor candidates due to the risk that intense ego dissolution could destabilize individuals predisposed to psychosis. Cardiac conditions and asthma may also present elevated risk.

Psychological risks - including acute distress, disorientation, and, in rare cases, lasting PTSD-type reactions following an uncontained experience - are recognized and underscore the importance of clinical setting, proper screening, and integration support.

07

What the Evidence Says

The most significant recent clinical data comes from GH Research, an Ireland-based biopharmaceutical company developing an inhalable synthetic formulation called GH001 (also known as mebufotenin). In February 2025, GH Research announced that its Phase 2b trial in patients with treatment-resistant depression met its primary endpoint - patients treated with GH001 showed a placebo-adjusted reduction of 15.5 points on the Montgomery-Asberg Depression Rating Scale (MADRS) by day 8. Among patients who achieved remission after their first active treatment, 91.7% remained in remission at 6 months, with only infrequent additional treatments.

A separate company, Beckley Psytech, is advancing a parallel clinical program across 40 sites in six countries. Both programs have shown rapid, clinically meaningful antidepressant effects in mid-stage trials, and 2026 is expected to be a pivotal year for further investigation.

Earlier observational studies found that people who used toad-derived 5-MeO in naturalistic settings reported improvements in depression, anxiety, and PTSD. A 2023 case study published in Frontiers in Psychiatry documented a woman with chronic, refractory PTSD whose symptoms nearly completely resolved after a single vaporized dose, with improvements sustained at 1, 3, 6, and 12 months of follow-up.

Important caveats: early-phase clinical evidence is encouraging but not yet conclusive. Larger, placebo-controlled trials with diverse populations and long-term follow-up are still needed.

08

The Conservation Question

Growing demand for toad-derived 5-MeO has raised serious ecological concerns. The Sonoran Desert toad is already believed to have been wiped out of California, where it was last seen in the wild in the 1970s. Herpetologists have warned that continued harvesting of the animals' venom secretions - which are extracted under stressful conditions - could cause population collapse. Some researchers and practitioners argue that the existence of chemically identical synthetic 5-MeO makes the use of toad secretionsvenom unnecessary, though some ceremony facilitators maintain that the synthetic and toad-derived compounds produce different experiences.

The National Park Service has publicly asked visitors not to handle or attempt to use toad secretions on federal land.

09

Clinical History

Some of the earliest and most rigorous observational research on 5-MeO in clinical settings was conducted through the work of Martin Polanco, MD, and Joseph Barsuglia, PhD, at Crossroads Treatment Center in Tijuana, Mexico, beginning in 2015. Dr. Polanco, who has over 25 years of clinical experience treating more than 5,000 patients with PTSD, addiction, traumatic brain injury (mTBI), and depression, funded Dr. Barsuglia to leave his VA fellowship and join Crossroads as Research Director - bringing scientific structure to what had been an observational clinical program.

At Crossroads, Barsuglia built a volunteer research team that began systematically collecting data on patients receiving 5-MeO, with a particular focus on the intensity of mystical experiences and their relationship to therapeutic outcomes. That research produced some of the first peer-reviewed evidence characterizing 5-MeO's effects in a clinical context. A landmark 2018 paper published in Frontiers in Psychology - "Intensity of Mystical Experiences Occasioned by 5-MeO and Comparison With a Prior Psilocybin Study" (Barsuglia, Davis, et al.) - found that 5-MeO consistently produced complete mystical experiences comparable in depth to those reported in leading psilocybin studies, a significant finding given the theoretical link between mystical experience and therapeutic benefit.

A 2018 study in the Journal of Psychopharmacology (Davis, Barsuglia, et al.) drew on a large international sample of 5-MeO users to document the epidemiology of its use - patterns of consumption, subjective effects, benefits, and adverse consequences - providing one of the first population-level pictures of how the compound was being used and experienced outside of laboratory settings.

Through The Mission Within, Dr. Polanco has continued this work with a focus on Special Operations Forces veterans. A 2023 real-world longitudinal case study published in Frontiers in Psychiatry (Ragnhildstveit, Khan, Seli, Barsuglia, et al.) documented a young woman with chronic, refractory PTSD who received a single vaporized dose of toad-derived 5-MeO and experienced clinically significant improvements sustained across 12 months of follow-up - the first longitudinal case study of 5-MeO for PTSD. Barsuglia's participation as a co-author reflects his continued role as a researcher and collaborator in this body of work.

Across both the Crossroads and The Mission Within programs, this research was presented at major scientific venues including the MAPS Psychedelic Science Conference, the West Los Angeles VA Psychiatry Grand Rounds, the Behavioral Pharmacology Research Unit symposium at Johns Hopkins, and the Association of Behavioral and Cognitive Therapies annual convention. The body of work from these programs helped establish the clinical and scientific rationale for 5-MeO as a fast-acting therapeutic compound and contributed foundational data that has informed subsequent industry-sponsored trials

10

  • GH Research PLC Phase 2b Trial Announcement (February 2025); Frontiers in Psychiatry - 5-MeO-DMT for PTSD: A Real-World Longitudinal Case Study (2023); Journal of Psychopharmacology - A Narrative Synthesis of Research with 5-MeO-DMT (Ermakova, Dunbar, Rucker, Johnson, 2021); Frontiers in Psychiatry - Short-Term Safety and Tolerability Profile of 5-MeO-DMT: A Systematic Review of Clinical Trials (2024); Frontiers in Pharmacology - Phase 1/2 Trial of GH001 in Treatment-Resistant Depression; UC Berkeley Center for the Science of Psychedelics; U.S. Drug Enforcement Administration / Federal Register (Schedule I placement, 2010-2011); National Geographic (Sonoran Desert toad coverage); The New York Times (Sonoran Desert toad / 5-MeO-DMT reporting, 2022); Psychology Today - From Toad Venom to Potential Antidepressant (April 2026); Lucid News - Federal Support for U.S. Psychedelic Research Accelerates 5-MeO-DMT Clinical Trials (March 2026)

BEGIN

On the other side of fear lies purpose.

APPLY HERE »